Aktienanalyse zu Progyny Inc (PGNY)PGNYProgyny Inc

Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Progyny Inc is a good buy right now, as it is currently priced at $26 with a forward P/E of 13.53, suggesting it is undervalued compared to its growth potential. Additionally, Wells Fargo's recent price target of $37 indicates a potential upside of 42% from the current price, which is a strong indicator of future growth.